

ECTH 2019
European Congress on
Thrombosis and Haemostasis
Glasgow, United Kingdom
2 - 4 October



INDEX 2019



The **ECTH**
2019 opening



DAY
1



DAY
2



DAY
3



“I don’t know how you normally deal with clogged pipes. But I use a pipe cleaner. This is not always without risks; it could damage the pipe and may even result in a leak.”

HANNE SKILLE

Page 41






WELCOME TO ECTH2019

It has been a great pleasure to welcome you to Glasgow, Scotland's most accessible city. The perfect location to bring together researchers and healthcare professionals from across Europe in the spirit of collaboration, discussion and the translation of science.

A lovely opportunity for established professionals to exchange knowledge and for young aspiring researchers to showcase their work.

This magazine displays highlights of ECTH 2019.

During the third edition of the European Congress of Thrombosis and Haemostasis (ECTH) we enjoyed three informative and most of all inspiring days filled with abstract presentations, state of the art lectures, plenaries and outstanding Science, Fast and Furious sessions.





PLENARY

Gordon Lowe

The first plenary lecture of ECTH2019 gives insight into the history of Scottish Medicine. An impressive journey through time by professor Gordon Lowe from the University of Glasgow. He told us about the oldest habitation Skara Brae (Orkney Islands) in Scotland, the first medicines found at burial sites in the form of grains of spiraea (used as an aspirin), and the Medical Renaissance between 1500 and 1750.

Let's also not forget about all the great scientist and intellectuals from the Scottish Enlightenment: David Hume, Adam Smith, James Hutton, Robert Burns and more.

"Scientific medicine started between 1750 and 1850. During that time the population of Scotland expanded from 1.3 to 2.9 million, which brought along major killer spreads in towns, such as tuberculosis, typhus, smallpox, measles and cholera."

"James Simpson, professor of midwifery, aimed to replace Ether in general anaesthesia with chloroform. To test this, he and his assistants inhaled volatile liquids in his house. It turned out – CHCl_3 worked out best. Since then it was used worldwide for surgery and midwifery."





With an impressive amount of facts and stories, Gordon Lowe offers us insight into the history of this small, cold and wet city with its proud medical history and developments in science and medicine that have a global impact.

**“Scottish
medical
history:
standing on
the shoulders
of giants.”**

**GORDON LOWE,
UNITED KINGDOM**





ZSUZSA BAGOLY

LUUK SCHERES

CATERINA CASARI

CLAIRE PEGHAIRE

SCIENCE, FAST AND FURIOUS

To stir things up a bit, eight young talented scientist with the highest abstract scores are challenged to present their studies in a different way. A TEDx inspired presentation, which takes the audience along on a journey and allows you to make your research accessible to a broader audience. Luuk Scheres, Caterina Casari, Zsuzsa Bagoly and Claire Peghaire are the first ones to inspire the audience with their story.





"In the Netherlands, we have *Buienradar*, an app which tells you exactly when you will need an umbrella as it predicts the weather for you. That is what we need with thromboembolism as well. Ultimately, we want to be able to predict who is at a high risk, who is at low risk, and when it might occur."

LUUK SCHERES

"It took 50 years for the scientific community to accept that Von Willebrand Disease (VWD) is different from haemophilia. Sometimes, I still feel like Von Willebrand Factor is in the shadow from all my colleagues who work on FVIII or FXI."

CATERINA CASARI



"Patients who suffered more severe strokes showed shorter clot-lysis. An unexpected result which caused me many sleepless nights."

ZSUZSA BAGOLY

"Luuk Scheres gave the best presentation by a PhD student I have ever seen at a scientific meeting. It was just like watching a TED talk by an expert."

A TWEET BY MICHAEL MAKRIS



CATERINA CASARI, FRANCE

"Haemostasis is the balance between clotting and bleeding. As a vascular biologist, I have always been fascinated by the complexity of our vascular system."

CLAIRE PEGHAIRE



CLAIRE PEGHAIRE, UNITED KINGDOM



OPENING CEREMONY

"We are extremely thrilled that you have chosen to host your third congress in Glasgow. It is a fascinating, dynamic and progressive city." With these welcoming words, the Depute Lord Provost Bailie Philip Braat welcomes us in the friendly city of Glasgow on behalf of the congregation of Glasgow.

As Gordon Lowe explained during his plenary lecture, Glasgow is a city with a long medical history that continues to benefit people from across the world. And that fits with this ECTH conference, according to the Depute Lord Provost. "ECTH is aiming to become a flagship event for the collection of knowledge surrounding haemostasis and thrombosis. It is an illuminating and thought-provoking congress.

We wish you a pleasant congress and a great time in this city of music, culture, science, medicine and banter."

After these warm, welcoming words, Raymond Mearns, the presenter of the opening ceremony, presents a Glaswegian survival guide. A humoristic and useful insight into Glaswegian slang. In just a few minutes we find out how we can order a *bevv* (a beer) in a cosy *boozer* (pub) and to tell our colleagues *yer bum's oot the windae!* (that they lack credibility).

Frits Rosendaal welcomes everyone on behalf of the ECTH Board, after which Jim Crawley, president of this years' host society, the British Society for Haemostasis & Thrombosis (BSHT), gets the



DEPUTE LORD PROVOST BAILIE PHILIP BRAAT



stage. Crawley is happy to see everyone in the city where his roots lie. The same city in which his grandfather was a medic - the person who gave Crawley his first microscope, which instigated his love for science. Of course, Crawley can't deny the elephant in the room: Brexit.

While we are not going to make any political statements, only controversial ones during the controversial corner, Crawley believes that we are stronger together. "Regardless of the outcome of Brexit, I believe now is the time to work together. And I hope ECTH contributes to working together for the greater good."

With that said, it is time to officially get to know each other during the welcome reception and wrap up the first successful day of ECTH2019.



FRITS ROSENDAAL,
THE NETHERLANDS



JIM CRAWLEY,
UNITED KINGDOM



RAYMOND MEARN,
UNITED KINGDOM







ATTENDEES' IMPRESSIONS

Emil Zâl Riahi

Research student in
Epidemiology, Denmark



For Emil Zal Riahi this is the first conference he has ever visited. And so far, it has been a pleasant experience: "The sessions on venous thrombosis were very interesting, and I feel like the Science, Fast and Furious is an interesting format."

"Besides trying to get to know new international colleagues and trying to learn a lot about interesting studies that could inspire me, I am also excited to give a presentation on Friday." During the Oral Communications on the consequences of venous thrombosis, Emil will present his study on Thromboembolic and Bleeding Complications in Patients with Atrial Fibrillation and Liver Cirrhosis. "ECTH2019 will most definitely be a success if this presentation goes well."

Sigrid Brækkan

Professor in Epidemiology, Norway

This is not the first time that Sigrid Brækkan, professor in Epidemiology from Norway, visits ECTH. In fact, she has attended all three conferences so far. "The quality of the congress is great. The variety of great speakers and all relevant European organisations gather here. Although it is still early in the conference, I'm especially looking forward to the sessions on thrombosis because I work

in that field. I hope that the conference will give me some new insights and will facilitate me in getting together with my European colleagues."





ATTENDEES' IMPRESSIONS

Rebekah Ellen Fretwell

Scientist in Haemostasis and Thrombosis, United Kingdom



"I am a scientist in the Haemostasis and Thrombosis laboratory at the Royal Hallamshire Hospital in Sheffield. My areas of interest are the new anticoagulants, DOACS, ADAM and the diagnosis of TTP. Today's lectures on ITP and TTP were therefore useful.

I am also a training lead at the hospital. I am looking at the posters and attending as many lectures to see if I can bring back new information to the students I teach.

ECTH offers a great mixture of science and provides a platform for different speakers and a variety of topics. We've got quite a good representation from Sheffield, consisting of haematology consultants and scientists. We've attended ECTH every year. The excellent content is probably why many of us return each year."

Christian Rørbakk

Account manager, Norway

relate to the matters that are dealt with during this conference. Therefore, I think it is important to freshen up my knowledge and find out more about new topics. So, I am definitely bringing back knowledge to the rest of the company."

Unlike many other visitors at ECTH, Christian Rørbakk is not a scientist, but an account manager at a pharmaceutical company. Yet, he finds it important to attend the conference to learn more about the products he markets on a daily base. "I work in sales. Usually, our industry is not very present during these conferences. At our company, we work with different types of drugs that







MEET THE EXPERT & HOW TO

During the second day of ECTH, attendees get the opportunity to ask questions and exchange views with some of the most prestigious experts in the world of thrombosis and haemostasis. The formula for these sessions: an informal setting, no PowerPoint-slides, and letting the questions from attendees lead the conversation.





Meet The Expert...

During the Meet the Expert sessions, attendees discuss a variety of topics, such as arterial thrombosis and coagulation defects, the developments in Von Willebrand Disease, thrombotic complications during pregnancy and the biochemistry of vitamin K.

Experts during these sessions:
Zsuzsanna Bereczky (Hungary), Alexander Bye (United Kingdom), Jeroen Eikenboom (The Netherlands), Catherine Bagot (United Kingdom), Francis Couturaud (France), Benoit Ho-Tin-Noé (France), Leon Schurgers (The Netherlands), Astrid van Hylckama Vlieg (The Netherlands), Dianne Kitchen (United Kingdom) and Michael Makris (United Kingdom).







How To...

The How To sessions give attendees insights on, among other things, how to diagnose and manage coagulopathies in hemoglobinopathies, how to serve on clinical trial boards, how to relate fibrin to microbial invasion and how to treat immune thrombocytopenia.

Experts during these sessions: Robert Ariens (United Kingdom), Michael Desborough (United Kingdom), Waleed Ghanima (Norway), Françoise Dignat-George (France), Nicola Mutch (United Kingdom), Steve Kitchen (United Kingdom), Kimberly Martinod (Belgium), Rafal Pawlinski (United States), Karen Vanhoorelbeke (Belgium) and Jeffrey Weitz (Canada).





ATTENDEES' IMPRESSIONS

Jeroen Eikenboom

Researcher and professor specialised in haemostasis and thrombosis, The Netherlands



"The main reason for me to be here is that I am part of the programme. I was one of the experts during the Meet the Expert-sessions. We discussed the importance of genetic testing and the possible role of the new recombinant

Von Willebrand Factor concentrate. Later on, I will give a lecture on Von Willebrand Disease.

You probably already know about most things that scientists and researchers talk about during this conference when you work in this field. But there are always small new points of view that are shared, which will influence or maybe even change your perspective on things. This conference will, therefore, really be a success if that happens."

Felix van der Meer

Researcher and practitioner, The Netherlands



"Programme components, such as the Science, Fast and Furious sessions, stimulate researchers and the broader audience who listen to such a lecture. It offers the younger people a stage to present their work in a different way, which is a nice change if you ask me."





PRIX D'HONNEUR DE LA JEUNESSE

Over the course of the congress, 20 awards were given out to support young researchers and scientific excellence.







STATE OF THE ART LECTURES


The State of the Art lectures allow us to broaden our knowledge of specific areas regarding thrombosis and haemostasis. During this first set of State of the Art lectures, Nicola Mutch (*United Kingdom*) discusses the dual role of platelets in fibrinolysis. Jeroen Eikenboom (*The Netherlands*) explains more about the management of Von Willebrand Disease. Leon Schurgers (*The Netherlands*) focuses on vascular calcification and Pablo García De Frutos (*Spain*) talks about the crosstalk of coagulation factors with endothelium.



PABLO GARCÍA DE FRUTOS, SPAIN

“There are many Von Willebrand Factor (VWF) concentrates on the market. Most of these concentrates are from a plasma source, but recently they also created one from a recombinant source. Which one should you use? And how should you dose it?”

JEROEN EIKENBOOM



“Vitamin K antagonists accelerate vascular calcification - from rat poison to drug.”

LEON SCHURGERS



LEON SCHURGERS, THE NETHERLANDS

“Gas6 specifically promotes the recruitment of inflammatory monocytes through the regulation of both CCR2 and CC12 during deep venous thrombosis.”

PABLO GARCÍA DE FRUTOS




JEROEN EIKENBOOM, THE NETHERLANDS

“Plasminogen associates with fibrin and directly with the platelet membrane. We found two locations of plasminogen on fibrin(ogen) and directly on the platelet surface.”

NICOLA MUTCH



NICOLA MUTCH, UNITED KINGDOM



“The top two causes of death (heart disease and stroke) are linked to intimal calcification.”

**LEON SCHURGERS,
THE NETHERLANDS**



"I am not a physician; as researchers, we don't very often get to interact with patients. Therefore, we organised meetings in cooperation with the French Haemophilia association to find out what patients expect from research. We found out that VWD-patients felt left behind. And when they asked us what we are developing regarding treatments of VWD, we realised this was something we did not focus on that much."

PLENARY

Cécile Denis

Another day, another plenary lecture. This time Cécile Denis (France) tells us about the latest developments in research on Von Willebrand Disease, a subject which we could spend a whole day talking about. However, Denis manages to inform the audience about the different types of mutations of VWD, the lifecycles of VWF and the intertwining with FVIII, but also explains more about current replacement treatments and gene therapy.



**“Coming down
to research:
VWF patients
often feel left
behind.”**

**CÉCILE DENIS,
FRANCE**







CONTROVERSIAL CORNER

“Everything that is said today does not have to be true, evidence-based, and you do not have to cite your work”, with these instructions Banne Nemeth kicks off the Controversial corner session. The Controversial corner is all about giving rise to public disagreement. This time, four heroes, as Nemeth describes them, dare to make a provocative statement.

Tilman Hackeng’s statement is as follows: ‘Never kill TFPI.’ The second statement, ‘Inflammation is the most important activator of clotting in vivo’, is a statement by Pablo García De Frutos. ‘Immediately stop all VKA treatments’, is what the daring statement by Leon Schurgers sounds like.

And lastly, Henri Spronk challenges the audience by stating that ‘Thrombin generation is useless for personal risk assessment’.

The statements cause heated discussions, yet entertaining encounters.

At the end of the Controversial corner Nemeth announced the winners of the three Poster Prizes. Myrthe Toorop, María Eugenia De La Morena-Barrio and Jayne Ellis all won a poster prize for outstanding scientific achievement.



"Who wants to take rat poison for a medicine?!"

LEON SCHURGERS

"What is inflammation: REDNESS, SWELLING, HEAT, PAIN!"

PABLO GARCÍA DE FRUTOS

"CLINICIANS WAKE UP, READ THE LITERATURE! Stop VKA treatment!"

LEON SCHURGERS

"There is no way you can tamper with TFPI. Never start inhibiting TFPI. If you don't have TFPI, you die."

TILMAN HACKENG

"We are losing what we mean by inflammation when we are talking about all these processes which are part of the healing process."

PABLO GARCÍA DE FRUTOS

"Even in gynaecology it's useless. There is no paper showing that thrombin generation can predict anything."

HENRI SPRONK

"Currently THE WHOLE WORLD is rebalancing the coagulation system."

TILMAN HACKENG

Disclaimer | The content of this session is not necessarily based on facts and no scientists should be harmed during their presentations.



LEON SCHURGERS, THE NETHERLANDS



HENRY SPRONK,
THE NETHERLANDS



PABLO GARCÍA DE FRUTOS, SPAIN



TILMAN HACKENG,
THE NETHERLANDS



CONGRESS DINNER

The Congress Dinner took place at the Glasgow Science Center. An impressive location, which allowed us to experience intriguing optical illusions and brain-bending puzzles.

Afterwards, it was time to network while enjoying great food. Last but not least, we ended the night with some traditional Scottish dancing.





STATE OF THE ART LECTURES

This second session of State of the Art lectures covers a variety of topics. Miriam Galbusera (*Italy*) gives the audience an overview of HUS, novel treatment. Yotis Senis (*United Kingdom*) discusses phosphatases in platelet signalling. Kimberly Martinod (*Belgium*) tells us everything about NETs and Samantha Gouw (*The Netherlands*) talks about everything you need to know about bleeding.



“Nets are a ‘hot topic’, particularly in thrombosis/haemostasis. Since they were initially described in 2004, there have been 2596 publications. And in relation to thrombosis/coagulation, there are around 400 publications.”

KIMBERLY MARTINOD



YOTIS SENIS, UNITED KINGDOM

“Being signalers, we wanted to figure out the mechanism, why these platelets aren’t responding.”

YOTIS SENIS



SAMANTHA GOUW, THE NETHERLANDS

“We saw that both during the acute phase of the disease and at remission, about half of HUS patients had normal serum C3 and plasma sC5b-9 levels.”

MIRIAM GALBUSERA




KIMBERLY MARTINOD, BELGIUM



MIRIAM GALBUSERA, ITALY

“As we expected: the bleeding rates decreased in severe hemophilia over the years.”

SAMANTHA GOUW



**“We aim to
create a
personal
health record:
standard
recording
and sharing
of health
data and
outcomes.”**

**SAMANTHA GOUW,
THE NETHERLANDS**



ATTENDEES' IMPRESSIONS

Andrew Danquah

Medical Science Manager,
United Kingdom



“What drove me to come to the conference was the scientific content. I work as a medical science manager at a pharmaceutical company. Our product portfolio primarily focuses on haemophilia, immunology, and genetic and metabolic

diseases. Over the past few days, I’ve heard a lot of new things, for example about ITP. During one of the lectures, the researcher spoke about some of the pathways in therapies and medicines in ITP. The inhibiting of the FCRN pathway turned out to be an important one. I’ve always thought this was an area the people were looking at in terms of treating ITP or haemophilia. So this was a great confirmation.”

Karina Vidovic

Researcher, Sweden

“The main reason for me to be here is to network. Working in a lab is an individualistic job and can get lonely sometimes. I am working on a haemostasis project in the lab and currently contributing to starting a new phase of transfusion medicine. I want to reach out to other researches in the world. Who knows, we might even work together at some point.

I am impressed by the work of some of the PhD students. It is nice to share knowledge with younger researchers.”





ATTENDEES' IMPRESSIONS

Evelien Kemna

Clinical chemist,
The Netherlands



Although the basic research presented at this conference is not directly something that Evelien Kemna deals with within her work as a clinical chemist, the conference is already a success after 1.5 days. "I just visited a lecture by a PhD student

who talked about the role of platelets in metastasis. That was new to me, I never thought about it consciously. It's great that I can take this kind of information back with me. I also like the more intimate and personal set ups during the conference, like the meet and greet with the experts. Great to have so much choice and to be able to join in at any time."

Esra Turan

General Haematologist, Turkey

young scientists. I am currently working on some studies, so maybe I'll send in a poster next time with the results."



"This really is an opportunity for me to get to know more about thrombosis from a broader perspective. In my country, we do not have much time to focus on or expand our knowledge of thrombosis. Most conferences on this subject are national, so ECTH is a great way to find out about other researchers across our border. Besides, I like to hear about the work of




SCIENCE, FAST AND FURIOUS


Just like during the first day, the Science, Fast and Furious-sessions on this last day of ECTH2019 are crowded. Four new young researchers get the stage to share their research in an accessible, innovative and inspiring way. Before Annemiek Dickhout, Hanne Skille, Bérangère Joly and Isabelle Salles-Crawley take the stage, Jean-Paul Toonen explains what the three ingredients of a great story or talk are. A good talk only has one theme. The talk is always divided into topics, and the perspective is not always the same.

“As a scientist you are familiar with telling your story from the perspective of a scientist. If you change your perspective once in a while, your story will become much more interesting.”

ANNEMIEK DICKHOUT



HANNE SKILLE



BÉRANGÈRE JOLY



ISABELLE SALLES-CRAWLEY



**“IF YOU
CHANGE YOUR
PERSPECTIVE
ONCE IN A
WHILE, YOUR
STORY WILL
BECOME
MUCH MORE
INTERESTING.”**

**JEAN-PAUL TOONEN,
THE NETHERLANDS**



BÉRANGÈRE JOLY, FRANCE

"I don't know how you normally deal with clogged pipes. But I use a pipe cleaner. This is not always without risks; it could damage the pipe and may even result in a leak."

HANNE SKILLE

"Platelets are amazing: they have multiple roles. For instance, they are more and more seen as immune cells and they release inflammatory mediators."

ISABELLE SALLES-CRAWLEY



ISABELLE SALLES-CRAWLEY, UNITED KINGDOM

"I'm going to tell you about a young French girl. Her story began with the diagnosis of classic otitis. But two weeks later it turned out she had an autoimmune TTP."

BÉRANGÈRE JOLY



HANNE SKILLE, NORWAY

"The chemokines were supposed to be on the cell, but all of a sudden they were going in the cell. What on earth was happening?"

ANNEMIEK DICKHOUT



ANNEMIEK DICKHOUT, THE NETHERLANDS



"A lot of activity about FXI inhibitors. Why is there so much interest? We want a new agent that would be at least as effective as we have right now and safer. Companies are looking for next-generation blockbuster drugs to use for anticoagulants."

"FXI is emerging as a promising target for new anticoagulants. Clinical trials comparing the benefit-risk profiles of FXI inhibitors and direct oral anticoagulant are underway."

PLENARY

Jeffrey Weitz

During the last plenary lecture of ECTH2019, Jeffrey Weitz, Professor and Executive Director of the Thrombosis and Atherosclerosis Research Institute at McMaster in Hamilton, gives insight into the inhibitor of factor XI. He discusses the new drugs and talks about new indicators. In his talk, it becomes clear that the ultimate goal of anticoagulant therapy is to attenuate thrombosis without increasing the risk of bleeding.



**“There is still
room to do
better.”**

**JEFFREY WEITZ,
CANADA**





SPORT ACTIVITY: CURLING

The brain is properly trained during ECTH. In between lectures, there is also room for physical training. During the break, there is time to get acquainted with a typical Scottish sport: curling.



SEE YOU IN 2021

That's a wrap. Three wonderful days packed with impressive research presentations, state of the art lectures, networking, meet and greets, TED-talk inspired presentations, great food and interesting poster viewings. After another successful edition of the European Congress on Thrombosis and Haemostasis, everyone is invited to meet again in two years time at the fourth edition of ECTH in Ghent, Belgium.

It promises to be another great event to discuss clinical topics and basic science, where professionals from all around the continent and beyond will meet again.

"I hope you all learned something new and met new people. Wish you all a safe journey home and see you in 2021 in Ghent, Belgium."

JIM CRAWLEY, UNITED KINGDOM

"ECTH is my favourite conference."

PETER LENTING, THE NETHERLANDS

#ECTH



ECTH 2019
European Congress on
Thrombosis and Haemostasis
Glasgow, United Kingdom
2 - 4 October





SPONSORS & PARTNERS

ECTH wishes to express gratitude to the following companies which, through their generosity, have helped to make this congress possible.



PARTNERS





Shionogi Europe

works to meet the needs of patients and the community around them.

From our beginnings over 140 years ago in Osaka, Japan, Shionogi & Co. Ltd. has built a strong heritage in research-based medicine. Shionogi Europe was launched in 2012 and is committed to applying our patients-first approach in everything we do.




 **SHIONOGI**
Visit us at www.shionogi.eu

PP-EU-NP-0003
Prepared: April 2019

Fast. Accurate. Connected.

The smarter diagnostic platform designed to deliver better health, better experiences and better value for everyone.

Smarter solutions, **better outcomes**
lumiradx.com



LumiraDx and the Flame logo are trademarks of LumiraDx UK and affiliates. © 2019 LumiraDx UK and affiliates. All rights reserved.
LumiraDx UK Ltd 09206123, Dumyat Business Park, Alloa, FK10 2PB, UK. Product not available in all countries. Not available in the USA.



Roche/Chugai

Hand in Hand in Haemophilia A

About Roche

At Roche, the lives of patients are at the heart of everything we do. Our aim is to improve the health, quality of life and wellbeing of people around the world.

We have been advancing medical science for over 120 years and are the world's largest biotechnology companyⁱ and a pioneer in the development of monoclonal antibodies (mAb). Roche has truly differentiated medicines and has the largest portfolio of approved mAb medicines, for cancer as well as a strong heritage in haematology.

Please see our website for further information:
<https://www.roche.co.uk/>

ⁱ Roche Pharmaceuticals, (2018). About Roche. [online]. Available at: <https://www.roche.com/about.htm> [Accessed September 2019].

ⁱⁱ Chugai Pharma, (2017). About us. [online]. Available at: <https://www.chugai.co.uk/about-us/chugai-group> [Accessed September 2019].

About Chugai

Chugai Pharma was founded in 1925 and became a member of the Roche Group in 2002. Since then, we have become one of the leading providers of biopharmaceuticals and therapeutic antibodies in Japan,ⁱⁱ specialising in rheumatology, haematology, oncology and gastroenterology.

At Chugai, our goal is to achieve innovation beyond imagination. We aim to add exceptional value through the creation of innovative medical products and services for the benefit of the medical community and health around the world.

Please see our website for further information:
<https://www.chugai-pharm.co.uk/>



More than you expect

Haemostasis solutions – innovative assays and analysers perfectly combined

aTTP

A medical emergency

For further information on aTTP, visit:
UnderstandingTTP.com

SANOFI GENZYME

aTTP; acquired Thrombotic Thrombocytopenic Purpura
SAGB.SA.19.08.1337 Date Prepared: August 2019

© 2019 Sanofi Genzyme. All rights reserved. SANOFI GENZYME and the Sanofi Genzyme Logo are registered trademarks of Sanofi Genzyme.



LIBERATE

the way they see the world

living life beyond haemophilia

LIBERATE
LIFE

Swedish Orphan Biovitrum (UK) Ltd
Suite 2, Riverside 3, Granta Park,
Great Abington, Cambridgeshire, CB21 6AD
www.sobi-uk.co.uk

 sobi



Bring Haemostasis **to light**

Thrombin Generation dedicated to the Clinical Lab

FULLY AUTOMATED

ADAMTS13

FXIII activity

Thrombin Generation

chromogenic assays

turbidimetric assays

clotting assays

technoclone

Ceveron® 100 series

AN EXPLOSION OF POSSIBILITIES



**LET'S MEET
AGAIN IN
GHENT**


mci *The Netherlands*
Congress organiser


visuele notulen
Online magazine



ECTH 2021
European Congress on
Thrombosis and Haemostasis
Ghent, Belgium
13 - 15 October